Professor Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center, Tel Hashomer, launched a clinical trial involving ivermectin, the broad-spectrum antiparasitic therapy that absolutely destroyed the novel coronavirus pathogen in an Australian lab experiment. Professor Schwartz undoubtedly has been scanning the use of ivermectin like TrialSite News has been reporting on it: the momentum behind the movement can’t be denied. The drug, Professor Schwartz posits, may be some form of cure.
TrialSite News recently showcased the study in Sheba Medical Center, Israel’s number one health provider and the 9th top health center worldwide. Recently, Schwartz informed The Jerusalem Post that the drug, now tested in mild to moderate cases, launched an investigation to determine if the regimen can significantly shorten the viral shedding period, allowing patients to post negative tests for COVID-19 and hence shorten the isolation period to just a few days. Currently, the infection can last at least two weeks and Gilead’s remdesivir helped reduce this amount by a few days. What if an economical and available drug could do far better?
Principal Investigator Comment
Professor Schwartz commented, “From a public health point of view, this is very important,” noting that if there was an economical and available cure such as this for the most part those that would fall ill would get better far more quickly and be back to work hence contributing to the economy’s productivity.
To date, The Jerusalem Post reports the study has enrolled 26 participants in the randomized, controlled trial: the protocol calls for 100 participants. Most of the recruits will be at what The Jerusalem Post refers to as state-run “coronavirus hotels.”
In 2015, a team of researchers won a Nobel Prize for the discovery of Ivermectin. Millions have been treated with the dru,g which has a known safety profile that clinical investigational teams can work with.
As TrialSite News has reported, in Peru thousands of been treated with ivermectin and the drug has been given the greenlight by the regulatory authorities. In Bolivia, regional governments are giving out hundreds of thousands of doses, while in Bangladesh TrialSite News interviewed doctor Tarek Alam that reported astounding results at the Bangladesh Medical College. TrialSite News has interviewed Dr. Jean-Jaque Rajter who treated patients in Broward County Florida. The observational protocol, approved by the Broward Health Board, led to materially positive results, which were recently uploaded to the preprint server. Now at least 23 random controlled trials involving ivermectin are ongoing, including those sponsored by the University of Kentucky and Johns Hopkins University. Sanford Health is purportedly also planning an ivermectin trial in the Great Plains region of America.
Professor Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center, Tel Hashomer
Call to Action: Follow the link to The Jerusalem Post article to learn more.